Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -7 of 7
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
3/26/2007
1.
Phase II Study of MOAB Ch14.18 with GM-CSF for Recurrent Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
under 21
NCI
POG-9347
POG-9347
Last Modified:
8/29/2005
 
First Published:
6/1/1994
2.
Phase I Study of Monoclonal Antibody Ch14.18 Combined With Sargramostim (GM-CSF) and Interleukin-2 After Autologous Bone Marrow or Peripheral Blood Stem Cell Rescue in Children With Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
21 and under
NCI
COG-A0935A
CCG-0935, CCG-0935A, NCT00005576
Last Modified:
9/1/1997
3.
Phase I Study of Monoclonal Antibodies Ch14.18 and R24 with IL-2 for Melanoma, Small Cell Lung Carcinoma, Soft Tissue Sarcoma, and Other GD2- and GD3-Positive Tumors (Summary Last Modified 09/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
NCI
WCCC-CO-9391
NCI-B94-0002, B94-0002
Last Modified:
6/1/1993
4.
Phase Ia/Ib Study of Chimeric Monoclonal Anti-GD2 Antibody 14.18 in Patients with Metastatic Melanoma (Summary Last Modified 06/93)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
UAB-185
NCI-B89-0005, B89-0005
Last Modified:
11/1/1994
5.
Phase I Study of Melanoma-Reactive Chimeric Anti-GD-2 Monoclonal Antibody 14.18 plus IL-2 for Refractory Metastatic Melanoma (Summary Last Modified 11/94)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
WCCC-CO-9097
NCI-B90-0014, B90-0014
Last Modified:
5/1/1995
6.
Phase I Study of Chimeric MOAB 14.18 plus GM-CSF for Metastatic Melanoma (Summary Last Modified 05/95)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 to physiologic 70
MDA-DM-90102
NCI-B93-0009, B93-0009
Last Modified:
3/1/1997
7.
Phase I Pilot Study of Chimeric MOAB 14.18 for Refractory Small Cell Lung Cancer (Summary Last Modified 03/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
NCI
MSKCC-93049A4
NCI-B93-0001, B93-0001
Select All on One Page
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute